A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Condition:   Hidradenitis Suppurativa (HS) Interventions:   Drug: Povorcitinib;   Drug: Placebo Sponsor:   Incyte Corporation Not yet recruiting

Source: ClinicalTrials.gov - November 17, 2022 Category: Research Source Type: clinical trials